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ABSTRACT
Background: Goblet cell hyperplasia with mucus hypersecretion contribute to increased morbidity and mor-
tality in bronchial asthma. We have reported that thioredoxin 1 (TRX1), a redox (reductionoxidation)-active
protein acting as a strong antioxidant, inhibits pulmonary eosinophilic inflammation and production of chemoki-
nes and Th2 cytokines in the lungs, thus decreasing airway hyperresponsiveness (AHR) and airway remodel-
ing in mouse asthma models. In the present study, we investigated whether endogenous or exogenous TRX1
inhibits goblet cell hyperplasia in a mouse asthma model involving chronic exposure to antigen.
Methods: We used wild-type Balbc mice and Balbc background human TRX1-transgenic mice constitutively
overproducing human TRX1 protein in the lungs. Mice were sensitized 7 times (days 0 to 12) and then chal-
lenged 9 times with ovalbumin (OVA) (days 19 to 45). Every second day from days 18 to 44 (14 times) or days
35 to 45 (6 times), Balbc mice were treated with 40 μg recombinant human TRX1 (rhTRX1) protein. Goblet
cells in the lungs were examined quantitatively on day 34 or 45.
Results: Goblet cell hyperplasia was significantly prevented in TRX1-transgenic mice in comparison with
TRX1 transgene-negative mice. rhTRX1 administration during OVA challenge (days 18 to 44) significantly in-
hibited goblet cell hyperplasia in OVA-sensitized and -challenged wild-type mice. Moreover, rhTRX1 admini-
stration after the establishment of goblet cell hyperplasia (days 35 to 45) also significantly ameliorated goblet
cell hyperplasia in OVA-sensitized and -challenged wild-type mice.
Conclusions: Our results suggest that TRX1 prevents the development of goblet cell hyperplasia, and also
ameliorates established goblet cell hyperplasia.
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INTRODUCTION
Bronchial asthma is a chronic inflammatory disease
of the lower airways, characterized clinically by re-
versible airway obstruction and airway hyperrespon-
siveness (AHR). The characteristic feature of asthma
is airway inflammation including infiltration by in-
flammatory cells such as eosinophils and lympho-
cytes, epithelial damage, and airway remodeling.1,2
Airway remodeling is observed in both children and
adults with asthma, and is characterized pathologi-
cally by goblet cell hyperplasia, airway wall edema,
and hyperplasia and hypertrophy of smooth muscle
cells and myofibroblasts.3,4 The structural changes in
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the airways are suggested to be responsible for thick-
ening of airway walls, airway flow limitation, and air-
way hyperresponsiveness (AHR) in patients with se-
vere asthma.5
Goblet cell hyperplasia in the airway is an impor-
tant pathologic characteristic of bronchial asthma, re-
gardless of disease severity, because previous studies
have shown that goblet cell hyperplasia with mucus
hypersecretion contributes to increased morbidity
and mortality.6-8 Indeed, the airways of patients who
die of severe acute asthma may have more than a 30-
fold increase of goblet cell hyperplasia compared with
patients who die of non-acute asthma.6 Therefore,
mucus hypersecretion by hyperplastic goblet cells in
the airways contributes to the pathogenesis of
asthma.9 In addition, goblet cell hyperplasia with mu-
cus hypersecretion is also observed in the lungs of
asthma model animals.10,11
Thioredoxin (TRX) is a redox (reductionoxida-
tion)-active protein. Two thioredoxins are cytosolic
(TRX1) and mitochondrial (TRX2).12 TRX1 plays a
role in the protein disulfidedithiol reducing system
with thioredoxin reductase and NADPH. Reduced
TRX1 reduces oxidized protein.13 Therefore, TRX1 is
thought to act as a strong scavenger for reactive oxy-
gen species (ROS) and as an antioxidant both in vitro
and in vivo.13-18 We previously showed that TRX1 in-
hibited AHR and recruitment of eosinophils into the
lungs in mouse models of asthma.19 Recently, we re-
ported that TRX1 prevents the development of airway
remodeling, eosinophilic pulmonary inflammation,
and AHR in a chronic antigen exposure asthma
model. Administration of recombinant human TRX1
(rhTRX1) protein also improves established airway
remodeling in this asthma model.20
In the present study, we used Balbc background
human TRX1-transgenic (Tg) mice, in which human
TRX1 protein was constitutively overproduced in the
lungs. We investigated whether endogenous or ex-
ogenous TRX1 was able to inhibit goblet cell hyper-
plasia in a murine model of chronic asthma induced
by exposure to ovalbumin (OVA). We also examined
whether rhTRX1 administration after the establish-
ment of airway remodeling ameliorated goblet cell
hyperplasia in this mouse asthma model.
METHODS
MICE AND REAGENTS
Wild-type Balbc mice were purchased from Charles
River Japan (Yokohama, Japan). Recombinant human
TRX1 protein (rhTRX1) was purchased from Oriental
Yeast Co., Ltd. (Shiga, Japan). rhTRX1 administration
did not induce any lethality or pulmonary inflamma-
tion in mice. TRX1 treatment did not increase the ac-
tivity of myeloperoxidase in the lungs of mice, as re-
ported previously.20
GENERATION OF BALBc BACKGROUND
TRANSGENIC MICE CONSTITUTIVELY OVER-
PRODUCING HUMAN TRX1
We previously established human TRX1 transgenic
mice that constitutively overproduce human TRX1
protein in the lungs using the human elongation fac-
tor (EF)-1α promoter.18 In this study, Balbc human
TRX1 transgenic mice were generated by mating
more than 5 times with wild-type Balbc mice, as re-
ported previously.20
STUDY DESIGN
The experimental protocol is shown in Figure 1.
Seven- to 10-week-old female Balbc TRX1-Tg posi-
tive (+), TRX1-Tg negative (−) littermate mice, or
wild-type Balbc mice were treated seven times with
an intraperitoneal injection of 10 μg sterile chicken
OVA (grade V, Sigma-Aldrich Chemical, St. Louis,
MO, USA) emulsified with 4 mg of sterile aluminum
hydroxide (Alu-Gel-S Suspension, Serva Electropho-
resis GmbH, Heidelberg, Germany) in a total volume
of 200 μL. The injections were given every 2 days
from days 0 to 12. These mice, each housed in a
closed box, were challenged for 48 minutes with 0.9%
saline (vehicle) (group A) or 5% OVA in 0.9% saline
(group B), administered via the airways by an ultra-
sonic nebulizer (Omron NE-U07, Tokyo, Japan),
amounting to a total of 1, 3, 6, 9, or 12 challenges.
Mice in groups C and D were sensitized with OVA
and then challenged for 48 minutes with 5% OVA in
0.9% saline as described above. Every second day
from days 18 to 44 (14 times in group C) or days 35 to
45 (six times in group D), mice were treated with an
intraperitoneal injection of 40 μg rhTRX1 suspended
in 100 μL of sterile phosphate-buffered saline (PBS).
On day 20, 25, 34, 46, or 54 (24 hours after the last
OVA aerosol), the mice were euthanatized and pul-
monary histopathologic analysis was performed.
HISTOLOGICAL EXAMINATIONS
The histological analysis was performed as reported
previously.16-20 Briefly, mice were euthanatized by an
intraperitoneal injection of pentobarbital sodium (2.5
to 5 mg per mouse). After the thorax had been
opened, the lungs were fixed immediately by intratra-
cheal instillation of 20% buffered formalin for 15 to 20
minutes at a constant pressure of 27 cmH2O. After
gross examination, the extracted tissues were placed
in 20% buffered formalin and further fixed for at least
24 hours. Sections (4 μm thick) were cut from
paraffin-embedded tissues and placed on poly-l-lysine
coated slides and then incubated overnight at 55 to
60℃. Deparaffinized sections were stained with he-
matoxylin and eosin (HE) and alcian blue-periodic
acid-Schiff (AB-PAS).
MORPHOMETRIC ANALYSIS
Serial paraffin sections of the right and left lungs of
TRX1 Prevents Goblet Cell Hyperplasia
Allergology International Vol 58, No3, 2009 www.jsaweb.jp 405
Fig. 1 Schematic summary of the experimental protocol. Group A: Mice were sensitized with 10 μg of ovalbumin 
(OVA) plus 4 mg of Al (OH)3 on days 0, 2, 4, 6, 8, 10, and 12, and then chalenged by inhalation of 0.9% saline 
on days 19, 22, 24, 27, 31, 33, 38, 41, and/or 45. Group B: Mice were sensitized with OVA, and then chalenged 
with 5% OVA (w/v) in 0.9% saline on days 19, 22, 24, 27, 31, 33, 38, 41, and/or 45. Group C: Mice were sensitized, 
and then chalenged with OVA, as described for group B. The mice were then treated intraperitonealy with 40 μg 
recombinant human TRX1 protein (rhTRX1) every 2 days from days 18 to 44. Group D: Mice were sensitized and 
then chalenged with OVA, as described for group B. The mice were injected intraperitonealy with 40 μg rhTRX1 
every 2 days from days 35 to 45. ＊ Mice were sacrificed for histopathological examination on days 25, 34, and 46.
Group A
day
0 2 4 6 8 10 12  18 19 20 22 24 25 27 31 33 34 38 41 45 46
i.p. (OVA) Aerosol (Saline)
Group B
0 2 4 6 8 10 12  18 19 20 22 24 25 27 31 33 34 38 41 45 46
i.p. (OVA) Aerosol (OVA)
Group C
0 2 4 6 8 10 12  18 19 20 22 24 25 27 31 33 34 38 41 45 46
i.p. (OVA) Aerosol (OVA)
TRX1
i.p. (OVA) Aerosol (OVA)
Group D






each mouse were made. Then, digitized video images
of the entire lung fields were captured by a Nikon
Microphot-FX microscope (Nikon, Tokyo, Japan)
with a CCD camera (DXM1200, Nikon). The video
output of the camera was sent to a microscopic-
imaging workstation (Nikon ACT-1, Nikon). Goblet
cells were defined as cells with large AB-PAS-stained
areas (greater than or equal to one-third of the height
of the epithelium from the basement membrane to
the luminal surface), and cells with sparse and light
staining were carefully excluded, as we have reported
previously.21 AB-PAS-positive goblet cells in the tra-
cheal epithelium were hand-counted in 5 to 10 ran-
dom high-power fields (hpfs) (observation at 400×) in
a double-blind manner, as reported previously.17,21 In
the serial sections, the tissues were stained with HE,
and the total number of epithelial cells was also
counted in the tracheal epithelium.
STATISTICAL ANALYSIS
Results are expressed as means ± standard error of
the mean. Comparisons among three or more groups
were made by ANOVA. Differences were considered
significant at P < 0.05. SAS 9.1.3 software, Japanese
edition (SAS Institute, Cary, NC, USA), was used for
statistical analysis.
RESULTS
ESTABLISHMENT OF GOBLET CELL HYPER-
PLASIA IN A CHRONIC ANTIGEN EXPOSURE
ASTHMA MODEL
Female wild-type Balbc mice were sensitized with
OVA, then challenged with OVA (group B) or 0.9%
saline (group A). We histologically analyzed the lung
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Fig. 2 Establishment of goblet cel hyperplasia in a chronic antigen exposure asthma model. 
The lung tissues were evaluated microscopicaly on days 25, 34, and 46 folowing alcian blue-pe-
riodic acid-Schif (AB-PAS) staining. Original magnification×100.





tissues by AB-PAS staining on days 25, 34, and 46
(Fig. 2). Severe airway inflammation was found in
OVA-sensitizedOVA-challenged mice (group B) but
not in OVA-sensitized0.9% saline-challenged mice
(group A) after day 25. The smooth muscle layer of
the airways was thickened in group B, but not in
group A, on days 34 and 46, but not on day 25. On
day 25, AB-PAS-positive goblet cells were observed in
the tracheal epithelium in group B, but not in group
A. On day 34, the maximum number of AB-PAS-
positive goblet cells was observed; thus, goblet cell
hyperplasia was established in the airways of group
B. On day 46, goblet cells were decreased in compari-
son with day 34. Moreover, AB-PAS-positive goblet
cells were barely evident in group B on day 54 (after
12 challenges with OVA) (data not shown). These
findings demonstrated that airway remodeling ac-
companied by airway inflammation, smooth muscle
hyperplasia, and goblet cell hyperplasia was estab-
lished by day 34. Maximum hyperplasia of goblet
cells was observed on day 34 in this chronic antigen
exposure asthma model.
OVERPRODUCTION OF TRX1 IN LUNGS PRE-
VENTS GOBLET CELL HYPERPLASIA
The promoter of human EF-1α is well known to have
strong promoter activity in various types of cells.22 A
previous study reported that the use of human EF-1α
promoter genes resulted in persistent and strong
gene expression in mouse lung.23 We previously es-
tablished human TRX1 transgenic (Tg) mice under
the control of the human EF-1α promoter, in which
human TRX1 protein was overproduced in the
lungs.18 In this study, we investigated whether over-
production of human TRX1 protein was able to pre-
vent hyperplasia of goblet cells in a mouse chronic
OVA-exposure model. Female Balbc TRX1 Tg (+)
mice and TRX1 Tg (−) littermate mice were OVA-
sensitized, then challenged with OVA (group B), or
0.9% saline (vehicle, group A). Mice were harvested
on day 34. Our repeated experiments showed that
smooth muscle hyperplasia and eosinophilic pulmo-
nary inflammation was prevented in the OVA-
sensitized and -challenged TRX1 Tg (+) mice, when
compared with TRX1 Tg (−) mice, as we have re-
ported previously20 (data not shown). AB-PAS-
positive goblet cells were greatly increased in the tra-
cheal epithelium of TRX1 Tg (−) mice. In contrast,
goblet cells were greatly decreased in the tracheal
epithelium of TRX1 Tg (+) mice (Fig. 3A). Quantita-
tive analysis revealed that AB-PAS-positive goblet
cells in the tracheal epithelium were significantly (p <
0.05) decreased in TRX1 Tg (+) mice, when com-
pared with control Tg (−) littermates (Fig. 3B). These
results show that overproduction of TRX1 in the
lungs prevents goblet cell hyperplasia in this chronic
antigen exposure model.
EXOGENOUS TRX1 INHIBITS GOBLET CELL HY-
PERPLASIA
We performed independent experiments (n = 6) to
examine whether rhTRX1 treatment during OVA
challenge was able to inhibit goblet cell hyperplasia
in this chronic OVA-exposure model. We performed
quantitative analysis of goblet cell hyperplasia on
days 20, 25, 34, and 46. The number of AB-PAS-
TRX1 Prevents Goblet Cell Hyperplasia
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Fig. 3 Overproduction of TRX1 in the lungs prevents gob-
let cel hyperplasia in a chronic antigen exposure model. Fe-
male Balb/c-background TRX1 transgene (Tg) positive (+) 
and control TRX1-Tg negative (-) litermate mice were sensi-
tized with OVA. Then, mice were chalenged with 0.9% sa-
line (Group A) or OVA (treated as Group B), as shown in 
Figure 1. (A) The lung tissues were evaluated microscopi-
caly on day 34 after AB-PAS staining. Original magnifica-
tion ×400. (B) Quantitative analysis. AB-PAS-positive 
goblet cels in the tracheal epithelium were hand-counted in 
5 to 10 random high-power fields (hpfs) (observation at 
×400) in a double-blind manner as described in the Meth-
ods section. Goblet cels were counted as AB-PAS-positive 
cels per hpf. Numbers of Tg (-) mice in groups A and B 
were 5 and 7, respectively. Numbers of Tg (+) mice in 
groups A and B were 4 and 3, respectively. ＊ P＜0.05 ver-






























positive goblet cells in the tracheal epithelium of
OVA-sensitizedOVA-challenged mice (group B) was
significantly (P < 0.05) greater than that in control
mice (group A) on days 20, 25, 34 and 46 (Fig. 4). We
had previously reported that the half-life of rhTRX1 is
51.3 hours in the mouse lung.17 Therefore, 40 μg of
rhTRX1 was administered intraperitoneally to OVA-
sensitized and -challenged mice (group C). Histologi-
cal analysis showed that goblet cell hyperplasia and
pulmonary inflammation were significantly (P < 0.05)
decreased in group C on days 20, 25, 34 and 46, when
compared with group B. The number of goblet cells
in group C was significantly (P < 0.05) lower than that
in group B on days 20, 25, 34 and 46 (Fig. 4). These
results showed that administration of hrTRX1 during
antigen challenge was able to prevent goblet cell hy-
perplasia in this chronic antigen exposure asthma
model.
TRX1 ADMINISTRATION AFTER ESTABLISH-
MENT OF AIRWAY REMODELING AMELIO-
RATES GOBLET CELL HYPERPLASIA
Next, we examined whether rhTRX1 administration
after establishment of airway remodeling would ame-
liorate goblet cell hyperplasia in this mouse asthma
model induced by chronic exposure to OVA. As we
previously reported, airway remodeling accompanied
by eosinophilic pulmonary inflammation and smooth
muscle hyperplasia was established by day 34 in this
mouse asthma model,20 and therefore we treated
OVA-sensitizedOVA-challenged mice with 40 μg of
rhTRX1 from days 35 to 45 every second day (group
D in Fig. 1), and performed histological analysis on
day 46. Goblet cell hyperplasia, as well as thickening
of the smooth muscle layer in the airways and pulmo-
nary inflammation, were markedly inhibited in group
D on day 46, in comparison with group B (Fig. 2).
Moreover, the number of goblet cells in group D was
significantly (P < 0.05) lower than that in group B on
day 46 (Fig. 4). These results show that exogenous
TRX1 administration after the establishment of air-
way remodeling was able to improve goblet cell hy-
perplasia in this murine chronic OVA-exposure
model.
DISCUSSION
Pulmonary inflammation, which is a characteristic of
asthma, results in increased oxidative stress in the
airways.24,25 Pulmonary inflammatory cells (particu-
larly eosinophils, macrophages, and neutrophils) re-
lease large amounts of ROS (reactive oxygen species)
and RNS (reactive nitrogen species) in asthma. In
fact, levels of the lysosomal enzymes myeloperoxi-
dase (MPO) (from neutrophils and monocytes
macrophages) and eosinophil peroxidase (EPO) are
increased in the peripheral blood, induced sputum,
and bronchoalveolar lavage (BAL) fluid of patients
with stable asthma.24 These increased levels of MPO
and EPO lead to the production of large amounts of
hydroxyl radical (OH−), which is a powerful ROS.
This increased oxidative stress (ROS and RNS) may
damage epithelial cells, and evoke AHR, which is
characteristic of asthma.24 Goblet cell hyperplasia is
thought to be induced after epithelial damage by en-
Imaoka H et al.
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Fig. 4 Prevention of goblet cel hyperplasia by administration of recombinant human 
TRX1 protein. For quantitative analysis, AB-PAS-positive goblet cels in the tracheal epi-
thelium were hand-counted in 5 to 10 random high-power fields (hpfs) (observation at 
×400) in a double-blind manner. ＊ P＜0.05 versus Group A, †P＜0.05 versus Group 





































dogenous ROS induced by various stimuli such as
neutrophil elastase,26 ozone,27 endotoxin,27 and diesel
engine emissions.30 ROS also directly stimulate hista-
mine release from mast cells, thus increasing mucus
secretion from airway epithelial cells in asthma.28 In
this study, we showed that both endogenous and ex-
ogenous TRX1 inhibited goblet cell hyperplasia in our
mouse model of asthma induced by chronic exposure
to OVA. Because TRX1 acts as a strong antioxidant,
and reduces the oxidization of proteins or the level of
H2O2, together with peroxiredoxin,13,25 the protective
effects of TRX1 against goblet cell hyperplasia in this
mouse asthma model may be at least partly attribut-
able to its antioxidant properties.
In patients with asthma, pulmonary inflammatory
cells including CD4+ T cells, eosinophils, and neutro-
phils produce large amounts of chemokines and Th2
cytokines including eotaxin, macrophage inflamma-
tory protein (MIP)-1α, RANTES (regulated on activa-
tion normal T cell expressed and secreted), IL-4, IL-5,
and IL-13.1,25 These chemokines and Th2 cytokines
may play a role in airway flow limitation and AHR in
asthma.29 In addition, it has been demonstrated that
the Th2 cytokines IL-4, IL-5, IL-9, and IL-13 induce
goblet cell hyperplasia in animal models and also in
vitro.30-33 A previous study showed that TRX1 directly
suppresses the activation of neutrophils by attenu-
ation of p38 MAPK activation induced by LPS and
other chemokines.34 It has been reported that TRX1
modulates cell signaling through ASK-135 and p53.36
TRX1 also activates the function of some transcrip-
tional factors such as NF-κB, p53, AP-1, Ref-1, and Sp-
1.13,25 We previously showed that TRX1 upregulates
the expression of IL-1 family cytokines (IL-1α, IL-1β,
IL-1 receptor antagonist [IL-1Ra], and IL-18) in a
mouse asthma model.19 Moreover, we recently found
that TRX1 decreases the expression of chemokines
and Th2 cytokines in the lung, including eotaxin,
MIP-1α and IL-13, in Balbc mice chronically ex-
posed to antigen.20 Therefore, TRX1 may inhibit gob-
let cell hyperplasia by inhibiting or activating certain
signal pathways (such as ASK-1 and p38 MAP kinase)
and transcription factors, the expression of cytokines
and chemokines, and the chemotaxis of inflammatory
cells, including neutrophils, in the lungs.
In this study, we did not perform recombinant
TRX1 protein-dose dependent experiments to see
whether recombinant TRX-1 can inhibit goblet cell
hyperplasia in a dose-dependent manner. Therefore,
we established human TRX1 transgenic mice consti-
tutively overproducing human TRX1 protein in the
lungs on a Balbc background. Here we showed that
human TRX1 Tg positive but not Tg negative mice
can prevent goblet cell hyperplasia. These experi-
ments may show that lung expression of TRX-1 pro-
tein can inhibit goblet cell hyperplasia in a dose-
dependent manner. A previous study demonstrated
that recombinant TRX1 inhibited CD4 coreceptor
functions and decreased IL-2 production by CD4 wild-
type T cells in vitro,37 suggesting that TRX1 can pre-
TRX1 Prevents Goblet Cell Hyperplasia
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vent antigen presenting cell (APC) funtion. However,
we previously showed TRX1 did not modulate serum
OVA-specific IgE levels in the mouse asthma
model.19 Our results suggest that TRX1 cannot in-
hibit APC function in vivo. Further analysis is needed
to confirm this issue.
It has been shown that several genes are upregu-
lated in association with goblet cell hyperplasia.
Among them, MUC family genes encode various mu-
cin glycoproteins that are primary secretory proteins
(e.g., MUC-1, MUC-2, and MUC-4).10 MUC5AC is the
most predominant MUC gene expressed in the air-
ways.10 It has been demonstrated that the level of
MUC5AC gene expression is increased in animal
models of asthma and in tissue samples from asth-
matic patients.10,38 In addition, it has been reported
that overexpression of the Gob-5 gene in airway epi-
thelia exacerbates AHR, goblet cell hyperplasia, mu-
cus overproduction, and eosinophil infiltration in a
mouse asthma model.39 Thus, TRX1 can prevent gob-
let cell hyperplasia by inhibiting the expression of
MUC genes andor the Gob-5 gene. Further analysis
will be needed to verify this possibility.
The treatment strategy for asthma control consists
mainly of the use of inhaled corticosteroids, because
the pathophysiological abnormality of this disease is
caused by pulmonary inflammation.40 However, ap-
proximately 5% of patients do not respond to this ther-
apy.41 In addition, current therapeutic approaches,
such as the use of corticosteroids to reverse estab-
lished airway remodeling, have had very limited suc-
cess in patients with severe asthma.42,43 Therefore, ef-
fective therapies that are targeted at severe asthma
are needed. We previously showed that exogenous
TRX1 inhibits AHR and pulmonary inflammation in a
mouse acute antigen exposure asthma model.19 Fur-
thermore, we recently demonstrated that exogenous
TRX1 administration during the allergen challenge
period inhibited smooth muscle hyperplasia and in-
flammation in the lungs of a chronic antigen expo-
sure mouse asthma model.20 Moreover, treatment
with rhTRX1 after the airway structural changes had
become established improved smooth muscle hyper-
plasia and thus inhibited AHR.20 In the present study,
we showed that endogenous and exogenous TRX1
was able to inhibit goblet cell hyperplasia in a murine
asthma model induced by chronic exposure to OVA.
In addition, rhTRX1 administration after the estab-
lishment of airway remodeling ameliorated goblet
cell hyperplasia in this model. Our present and previ-
ous studies suggest that TRX1 has potential utility as
a new therapy for patients with severe asthma resis-
tant to treatment with corticosteroids.
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